Cisplatinum plus Epirubicin Alternated with Cyclophosphamide plus 5-Fluorouracil in Ovarian Cancer

Summary

Fifty-two patients with ovarian cancer (post surgical residual tumor) were treated with the combination of platinum + epirubicin (PE) (P 50mg/m², E 60 mg/m²) alternated with cyclophosphamide + 5-fluorouracil (CF) (C 800 mg/m², F 600 mg/m²). The treatment was repeated every 28 days for a maximum of 10 cycles. Forty-three patients were evaluable for response. Complete remission (CR) was achieved in 13 (30%) patients (evaluated by second-look), while partial remission (PR) was achieved in 6 (14%) patients for a mean duration of 27 and 14 months, respectively. Eleven out of 13 patients with CR and 5 out of the nonevaluable patients are alive and do not show signs of disease after a mean follow-up of 29 + months (range 19-36). The main factors that conditioned complete remission were the tumor residue and performance status of the patient.

Key words:

• poly chemotherapy
• ovarian cancer